Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
OtherPractice

Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers

Mathieos Belayneh and Christina Korownyk
Canadian Family Physician September 2016; 62 (9) e523;
Mathieos Belayneh
Medical student at the University of Alberta in Edmonton.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina Korownyk
Associate Professor in the Department of Family Medicine at the University of Alberta.
MD CCFP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Clinical question

Are α-blockers effective in reducing lower urinary tract symptoms in benign prostatic hypertrophy (BPH)?

Bottom line

As a first-line therapy, α-blockers are effective. Compared with placebo, around 1 in 10 patients have improved BPH symptoms or avoid symptom progression, while about 1 in 50 patients experience hypotension or dizziness. Mainly indirect comparisons suggest doxazosin and terazosin are slightly more effective but have increased risk of adverse events.

Evidence

  • In a systematic review of 26 RCTs of α-blockers versus placebo, peak urinary flow (Qmax) improved by 1.32 mL/s and International Prostate Symptom Score (IPSS) decreased by 1.92.1

  • Meta-analysis of 124 RCTs comparing doxazosin, terazosin, alfuzosin, and tamsulosin found improvement in Qmax (by 1.95, 1.21, 1.07, and 1.07 mL/s, respectively) and symptoms (changes in IPSS of −3.67, −3.37, −2.13, and −2.07, respectively).2

    • -Doxazosin performed statistically significantly better for both outcomes. There was a statistically significant increase in adverse events with doxazosin and terazosin.

  • A systematic review of 23 RCTs (20 821 patients) compared α-blockers to finasteride3 and found it was inferior to doxazosin and terazosin for Qmax and IPSS at 1 year, but noninferior to tamsulosin. Finasteride and dutasteride are similarly effective.4

  • An RCT of 3047 men compared placebo with doxazosin, finasteride, and a combination.5 Compared with placebo, doxazosin reduced symptom progression (number needed to treat [NNT] of 15 over 4 years) and increased hypotension (number needed to harm [NNH] of 58) and dizziness (NNH = 48).

  • In 3 pooled RCTs (955 patients),6 more men taking alfuzosin (76%) had a 3-point improvement or greater in IPSS than men taking placebo did (62%; NNT = 7).

Context

  • Guidelines recommend α-blockers as first-line therapy in men with symptomatic BPH.7

  • Clinically meaningful improvement of IPSS is 2 to 6 points or more, depending on baseline score.8

  • Transurethral resection of the prostate improves Qmax about 10 mL/s and decreases IPSS by 16.7.9

  • The α-blockers are associated with increased risk of falls (NNH = 589) and fracture (NNH = 1667).10

  • A 2013 systematic review comparing α-blockers to combination therapy with α-reductase inhibitors showed that combination therapy was effective for enlarged prostates and treatment for longer than 1 year.11

Implementation

Observational data suggest BPH is correlated with obesity and reduced physical activity.12 Predicting progression to urinary retention is difficult, although high prostate gland volume, elevated prostate-specific antigen level, and older age might increase risk.7 In higher-risk patients, it might be reasonable to add α-reductase inhibitors, as they have reduced urinary retention (NNT = 60) and surgical intervention (NNT = 32) over 4 years.5 Side effects including adverse sexual effects (NNH = 15) should be discussed.3

Notes

Tools for Practice articles in Canadian Family Physician (CFP) are adapted from articles published on the Alberta College of Family Physicians (ACFP) website, summarizing medical evidence with a focus on topical issues and practice-modifying information. The ACFP summaries and the series in CFP are coordinated by Dr G. Michael Allan, and the summaries are co-authored by at least 1 practising family physician and are peer reviewed. Feedback is welcome and can be sent to toolsforpractice{at}cfpc.ca. Archived articles are available on the ACFP website: www.acfp.ca.

Footnotes

  • Competing interests

    None declared

  • The opinions expressed in Tools for Practice articles are those of the authors and do not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Nickel JC,
    2. Sander S,
    3. Moon TD
    . A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 2008;62(10):1547-59.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Yuan JQ,
    2. Mao C,
    3. Wong SY,
    4. Yang ZY,
    5. Fu XH,
    6. Dai XY,
    7. et al
    . Comparative effectiveness and safety of monodrug therapies for lower urinary tract symptoms associated with benign prostatic hyperplasia: a network meta-analysis. Medicine (Baltimore) 2015;94(27):e974.
    OpenUrlPubMed
  3. 3.↵
    1. Tacklind J,
    2. Fink HA,
    3. Macdonald R,
    4. Rutks I,
    5. Wilt TJ
    . Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev 2010;(10):CD006015.
  4. 4.↵
    1. Nickel JC,
    2. Gilling P,
    3. Tammela TL,
    4. Morrill B,
    5. Wilson TH,
    6. Rittmaster RS
    . Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 2011;108(3):388-94.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. McConnell JD,
    2. Roehrborn CG,
    3. Bautista OM,
    4. Andriole GL Jr.,
    5. Dixon CM,
    6. Kusek JW,
    7. et al
    . The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349(25):2387-98.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Roehrborn CG,
    2. Van Kerrebroeck P,
    3. Nordling J
    . Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003;92(3):257-61.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Nickel JC,
    2. Méndez-Probst CE,
    3. Whelan TF,
    4. Paterson RF,
    5. Razvi H
    . 2010 Update: guidelines for the management of benign prostatic hyperplasia. Can Urol Assoc J 2010;4(5):310-6.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Barry MJ,
    2. Williford WO,
    3. Chang Y,
    4. Machi M,
    5. Jones KM,
    6. Walker-Corkery E,
    7. et al
    . Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995;154(5):1770-4.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Milonas D,
    2. Verikaite J,
    3. Jievaltas M
    . The effect of complete transurethral resection of the prostate on symptoms, quality of life, and voiding function improvement. Cent European J Urol 2015;68(2):169-74.
    OpenUrlPubMed
  10. 10.↵
    1. Welk B,
    2. McArthur E,
    3. Fraser LA,
    4. Hayward J,
    5. Dixon S,
    6. Hwang YJ,
    7. et al
    . The risk of fall and fracture with the initiation of a prostate-selective α antagonist: a population based cohort study. BMJ 2015;351:h5398.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Füllhase C,
    2. Chapple C,
    3. Cornu JN,
    4. De Nunzio C,
    5. Gratzke C,
    6. Kaplan SA,
    7. et al
    . Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol 2013;64(2):228-43.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Lin PH,
    2. Freedland SJ
    . Lifestyle and lower urinary tract symptoms: what is the correlation in men? Curr Opin Urol 2015;25(1):1-5.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 62 (9)
Canadian Family Physician
Vol. 62, Issue 9
1 Sep 2016
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers
Mathieos Belayneh, Christina Korownyk
Canadian Family Physician Sep 2016, 62 (9) e523;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers
Mathieos Belayneh, Christina Korownyk
Canadian Family Physician Sep 2016, 62 (9) e523;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Clinical question
    • Bottom line
    • Evidence
    • Context
    • Implementation
    • Notes
    • Footnotes
    • References
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Non-Surgical Management of Urinary Incontinence
  • Google Scholar

More in this TOC Section

Practice

  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
  • Spontaneous pneumothorax in children
Show more Practice

Tools for Practice

  • Testosterone supplementation for men
  • Time to challenge penicillin allergy labels
  • Antibiotics for acute diverticulitis
Show more Tools for Practice

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire